Spencer Wilson, MD
Gastroenterology · Indianapolis, INNPI 1679731046
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 711 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 33.4% of the total.
Across 711 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$782
- Bristol Myers Squibb$559
- Pfizer$465
- plus $3K from 32 others
What the payments were for
- Food & beverage$12,21299%
- Education$1621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 202 | $4,127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 123 | $2,127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 90 | $1,390 |
| Johnson & Johnson | 51 | $782 |
| Bristol Myers Squibb | 44 | $559 |
| Pfizer | 33 | $465 |
| Ironwood Pharmaceuticals, Inc | 18 | $296 |
| Nestle Healthcare Nutrition Inc. | 15 | $237 |
| Regeneron Healthcare Solutions, Inc. | 13 | $221 |
| Gilead | 12 | $194 |
| Ardelyx, Inc. | 10 | $168 |
| Redhill Biopharma Inc. | 8 | $141 |
| Braintree Laboratories, Inc. | 8 | $138 |
| Celltrion USA Inc. | 8 | $138 |
| Sanofi | 5 | $132 |
| Romark Laboratories, LC | 6 | $120 |
| Phathom Pharmaceuticals, Inc. | 7 | $119 |
| Daiichi Sankyo Inc. | 8 | $114 |
| Ferring Pharmaceuticals Inc. | 7 | $106 |
| Ipsen Biopharmaceuticals, Inc | 5 | $104 |
| Madrigal Pharmaceuticals | 4 | $91 |
| Aimmune Therapeutics, Inc. | 4 | $88 |
| UCB, Inc. | 6 | $82 |
| Sandoz | 4 | $68 |
| Lilly USA, LLC | 2 | $45 |
| Intercept Pharmaceuticals, Inc. | 3 | $44 |
| Boston Scientific | 1 | $35 |
| Medtronic | 2 | $34 |
| Mauna Kea Technologies, Inc. | 1 | $33 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Concordia Pharmaceuticals Inc. | 2 | $25 |
| Novo Nordisk | 1 | $24 |
| Axonics, Inc. | 1 | $19 |
| Vivus LLC | 1 | $17 |
| Amgen | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Organon | 1 | $14 |
| AstraZeneca | 1 | $11 |
How this compares
$12,374 in reported general payments places this provider in the 85th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 11 | $74,927 |
| XifaxanRifaximin | 24 | $73,809 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 58 | $9,374 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 122 | $8,306 |
| Mesalamine | 25 | $5,602 |
| Ursodiol | 30 | $4,704 |
| Colestipol Hcl | 31 | $3,158 |
| Pantoprazole Sodium | 225 | $2,313 |
| Budesonide DrBudesonide | 23 | $1,822 |
| Lansoprazole | 26 | $1,200 |
| Omeprazole | 124 | $1,064 |
| Esomeprazole Magnesium | 22 | $907 |
| Dicyclomine Hcl | 30 | $731 |
| Azathioprine | 26 | $634 |
| Sucralfate | 11 | $603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $2,127 | $73,80924 claims |
| Braintree Laboratories, Inc.Sutab | $138 | $9,37458 claims |
| SandozLansoprazole | $68 | $1,20026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in Indianapolis
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
- David PoundIndianapolis$137K
- Glen LehmanIndianapolis$87K
- Samer GawriehIndianapolis$78K
- Stuart ShermanIndianapolis$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.